Syntara Limited has released a press release.
After FDA Review PXS Accelerates Plans for Combination Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- PXS announces positive interim data from myelofibrosis trial
- Investor Presentation
- PXS Releases Promising Interim Data from Skin Scarring Study
- PXS to Receive Stg2.9m from Parkinsons UK for New Trial
- Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology
Later from Syntara
- PXS Announces Encouraging Results from Phase 1c Scar Study
- Final Set of Interim Data from PXS-5505 in Myelofibrosis
- PXS to Receive Prepayment of 2023 Research Tax Incentive
- PXS Company Restructure Sale of Mannitol Business
- Half Yearly Report and Accounts
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara